Results 151 to 160 of about 15,581 (231)

Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer. [PDF]

Clin Epigenetics, 2022
Hogg SJ, Motorna O, Kearney CJ, Derrick EB, House IG, Todorovski I, Kelly MJ, Zethoven M, Bromberg KD, Lai A, Beavis PA, Shortt J, Johnstone RW, Vervoort SJ.   +13 more
europepmc   +1 more source

Epigenome Modifying Tools In Asthma [PDF]

, 2015
Adcock,, Brook, PO, Durham, AL, Perry, M
core   +1 more source

BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia. [PDF]

Cell Death Dis, 2022
Zhong M, Gao R, Zhao R, Huang Y, Chen C, Li K, Yu X, Nie D, Chen Z, Liu X, Liu Z, Chen S, Lu Y, Yu Z, Wang L, Li P, Zeng C, Li Y.   +17 more
europepmc   +1 more source

Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections. [PDF]

Proc Natl Acad Sci U S A, 2022
Modukuri RK, Yu Z, Tan Z, Ta HM, Ucisik MN, Jin Z, Anglin JL, Sharma KL, Nyshadham P, Li F, Riehle K, Faver JC, Duong K, Nagarajan S, Simmons N, Palmer SS, Teng M, Young DW, Yi JS, Kim C, Matzuk MM.   +20 more
europepmc   +1 more source

Combined inhibition of BET bromodomain and mTORC1/2 provides therapeutic advantage for rhabdomyosarcoma by switching cell death mechanism. [PDF]

Mol Carcinog, 2022
Srivastava RK, Guroji P, Jin L, Mukhtar MS, Athar M.   +4 more
europepmc   +1 more source

Correction to: BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia. [PDF]

Cell Death Dis, 2022
Zhong M, Gao R, Zhao R, Huang Y, Chen C, Li K, Yu X, Nie D, Chen Z, Liu X, Liu Z, Chen S, Lu Y, Yu Z, Wang L, Li P, Zeng C, Li Y.   +17 more
europepmc   +1 more source

Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo. [PDF]

J Clin Invest, 2022
Falcinelli SD, Peterson JJ, Turner AW, Irlbeck D, Read J, Raines SL, James KS, Sutton C, Sanchez A, Emery A, Sampey G, Ferris R, Allard B, Ghofrani S, Kirchherr JL, Baker C, Kuruc JD, Gay CL, James LI, Wu G, Zuck P, Rioja I, Furze RC, Prinjha RK, Howell BJ, Swanstrom R, Browne EP, Strahl BD, Dunham RM, Archin NM, Margolis DM.   +30 more
europepmc   +1 more source

Therapeutically targeting oncogenic CRCs facilitates induced differentiation of NB by RA and the BET bromodomain inhibitor. [PDF]

Mol Ther Oncolytics, 2021
Alleboina S, Aljouda N, Miller M, Freeman KW.   +3 more
europepmc   +1 more source

BET Bromodomain Inhibitor ZEN-3694 [PDF]

, 2020
openaire   +1 more source

BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor-Positive Breast Cancer via Induction of miR-34a-5p. [PDF]

Clin Cancer Res
Liu R, Wang X, Branigan TB, Griffin D, McSweeney C, Hao J, Pantelidou C, Herbert ZT, Jadhav H, Shapiro GI.   +9 more
europepmc   +1 more source